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PSU4
VENTRAL, UMBILICAL,AND INGUINAL HERNIA: REVIEW OF
THE CURRENT LITERATURE
De Jonge P1, Llyod A1,Tan R2, Narewska J1, Doyle S3, Nafees B1
1UBC, UK, UK, 2Ethicon, Livingston, UK, 3United Biosource
Corporation, London, London, UK
OBJECTIVES: To provide a comprehensive overview of existing
literature on inguinal, ventral, and umbilical hernias in the UK,
US, France, Germany, and Italy in four independent areas: 1) epi-
demiology; 2) treatment guidelines and management; 3) health-
related quality of life; and 4) economic burden. METHODS:
Systematic reviews and meta-analyses were reviewed ahead of
any single studies. Studies included in the systematic reviews
were not reviewed independently. Where systematic reviews were
not available, the next highest level of evidence was identiﬁed.
RESULTS: Seven studies examining incidence of inguinal (5),
ventral (2), and umbilical hernia (0); 17 studies of HRQL in
inguinal hernia repair (none in ventral or umbilical hernia
repair); 4 systematic reviews and 22 costing studies of inguinal
hernia repair (4 ventral hernia costing studies; none for umbili-
cal); and 10 published guidelines on inguinal hernia repair only
(none for France, Italy, or Germany) were identiﬁed. No preva-
lence studies were found and incidence data was limited to hernia
repair procedures and recurrences versus true incidence of
hernia. Open mesh repair appears most common due to safety,
ease of technique, low recurrence rates and cost although laparo-
scopic repair has potential beneﬁts over open mesh. Hernia
repair generally leads to improved HRQL regardless of surgical
technique. Mixed evidence supports LH patients having better
HRQL, post-operative pain outcomes, return to work and usual
daily activities proﬁle following inguinal hernia surgery than OH
patients. The inclusion of indirect costs such as absenteeism and
presenteeism can signiﬁcantly reduce or eliminate cost differ-
ences between laparoscopic and open repair as noted in TEP pro-
cedures. CONCLUSIONS: Although hernia repair is a common
procedure, its epidemiology, treatment guidelines and manage-
ment recommendations are not well referenced in the literature.
Evidence based decision-making would be improved through
reporting of real world, observational, longitudinal hernia repair
data.
POSTER SESSION III
ALLERGY-ASTHMA
PAA1
CLINICAL EFFECTIVENESS OF ADJUSTABLE DOSING SINGLE
INHALER BUDESONIDE/FORMOTEROL FOR ASTHMA AND
BUDGET IMPACT ANALYSIS
Kaczor M, Becla L,Wojcik R, Dardzinski W, Walczak J, Nogas G
Arcana Institute, Cracow, Poland
OBJECTIVES: To compare budesonide/formoterol in single
inhaler with budesonide + formoterol from separate inhalers and
adjustable dosing of single inhaler budesonide/formoterol with
ﬁxed dosing in patients with moderate and severe persistent
asthma. To assess national payers budget impact. METHODS:
The clinical effectiveness analysis was performed according to
Cochrane Collaboration Guidelines. Budget impact model
consist of 3 refund settings scenarios for single inhaler, adjustable
dosing budesonide/formoterol. RESULTS: Budesonide/for-
moterol in single inhaler vs budesonide + formoterol from sepa-
rate inhalers Three RTC were included. No signiﬁcant difference
in quality of life and others parameters of disease symptoms
control. Only dysphonia presence was statistically lower in single
inhaler group (I 3 months follow-up), OR = 0.12 (0.02; 0.88).
Fixed dosing versus adjustable dosing 7 RTC were included. No
signiﬁcant difference in quality of life and number of patients
with at least one disease exacerbation (three months follow-up).
Metaanalysis of trials with 5–6 months follow-up showed lower
disease exacerbation risk with adjustable dosing, RR = 0.56
(0.40; 0.77). No signiﬁcant difference in frequency of severe
disease exacerbation, multiple exacerbation of disease, necessity
of oral administration of corticosteroids and additional therapy.
Lower risk of hospitalization/emergency treatment with
adjustable dosing, RR = 0.65 (0.43; 0.98) was observed. Both
treatments were well tolerated but the adverse event proﬁle was
statistically lower in adjustable dosing—less sever, asthma
related adverse events, OR = 0.12 (0.02; 0.72) in three months
follow-up was noticed. Budget impact model Single inhaler
budesonide/formoterol refund consequences per year: 0.4 million
sold drug units; 3248 avoided medical visits; 518 avoided hos-
pital/emergency asthma exacerbations treatments; 27.7% reduc-
tion in drugs intake volumen; 11–32 millions PLN national
insurer budget savings. CONCLUSIONS: Single inhaler budes-
onide/formoterol therapy, especially adjustable dosing, is a clin-
ically effective and well-tolerated treatment for patients with
asthma. Refund of this therapy may generate savings for national
insurer budget.
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Scamarcia A4, Schiappoli M6,Valle C9,Verna N7, Giaquinto C10
1Pbe consulting,Verona, Italy, 2Rho Hospital, Cerchiate di Pero (MI),
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OBJECTIVES: Efﬁcacy of sublingual-immunotherapy (SLIT) has
been assessed by several studies and conﬁrmed by the WHO
ARIA paper and Cochrane review. Effect of SLIT on consump-
tion of medical resources is yet to be proven in a naturalistic
environment. METHODS: A network of specialist allergy
centres provided data on access to medical care for patients
affected by allergic rhinitis (R) with or without asthma (A)
enrolled in February 2004. Patients affected by grass pollen
allergy, documented by allergen tests, were included in this analy-
sis and split into SLIT patients and patients treated with symp-
tomatic drugs (controls). Outcome measures included use of
medications, SLIT, routine care visits, other specialist visits, hos-
pital admissions and tests. Costs were assessed from the per-
spective of the Italian NHS; unit costs were obtained from
published sources (national tariffs for visits and tests; market
prices for drugs and immunotherapies). Average cost/patient for
the ﬁrst year after enrolment was produced. RESULTS: One-
hundred and two patients were analyzed (SLIT/Controls 54/48;
M/F 56/46; mean age 30 + 13 years; mean follow-up 376 + 29
days). Demographics were comparable in the two groups.
Overall per patient yearly cost of treatment was higher in SLIT
patients, in the whole sample (€311 vs. €180/patient), in the R
(€288 vs. €116) and R + A (€362 vs. €230) subpopulations, with
R + A patients generating more costs than R patients in both
groups. Nevertheless considerable savings were obtained in the
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cost of symptomatic drugs (−22% for R; −34% for R + A) in
SLIT patients. CONCLUSIONS: Use of symptomatic drugs is an
important indicator of effective allergy control: other studies
have shown SLIT can reduce the use of drugs for asthma and
rhinitis, but this is the ﬁrst time this outcome is demonstrated in
a routine care population, in the medical practice environment
of an observational study, and yet at the ﬁrst year of treatment.
PAA3
COST OF MANAGING ASTHMA EXACERBATIONS WITH
STABLE DOSING OF SALMETEROL/FLUTICASONE
COMBINED PRODUCT (SFC) COMPARED WITH 
ADJUSTABLE MAINTENANCE DOSING (AMD) OF
FORMOTEROL/BUDESONIDE COMBINED PRODUCT (FBC) 
IN POLAND
Orlewska E1, Cel M2, Glogowski C2
1Centrum Farmakoekonomiki, Warsaw, Poland, 2GSK Commercial Sp.
z o.o, Warsaw, Poland
OBJECTIVES: Exacerbations—consequence of poor control of
asthma—are the main component of high cost of this disease.
The aim of the study was the cost comparison of managing
asthma exacerbations with two types of treatment: stable dosing
of SFC and AMD of FBC. METHOD: The analysis was per-
formed from health-care payer perspective, based on Polish data
on health-care resource utilisation and unit cost obtained from
COAX study, estimating cost of asthma exacerbation managed
in primary and secondary care in Poland. Data on incidence of
asthma exacerbations in two types of treatment were derived
from 1-year CONCEPT Trial—the only available double blind,
double dummy, randomized study in adults with persistent
asthma, comparing stable dosing SFC with AMD of FBC.
RESULTS: Study population was 688 patients (344 in each treat-
ment arm). 11.3% patients on stable dosing of SFC experienced
an asthma exacerbation compared with 17.7% patients receiv-
ing AMD of FBC. There were 48% fewer exacerbations in the
stable dosing SFC group than in AMD with FBC (50 vs. 96 exac-
erbations respectively). The incidence of asthma exacerbations
requiring oral steroids or an emergency room visit/hospitaliza-
tion was 47% lower for the stable dosing SFC group than for
AMD with FBC (adjusted annual mean rate, 0.18 vs 0.33; P =
0.008). The total annual direct health care costs of managing
exacerbations for the stable dosing SFC group was PLN 19.833
compared with PLN 34.936 for the AMD with FBC group. Dif-
ference in annual costs of managing exacerbations was PLN
15.103 (EUR 1 = PLN 4,02; year 2005). CONCLUSION: Stable
dose treatment with salmeterol/ﬂuticasone combined product of
adult patients with persistent asthma is more effective than the
adjustable maintenance dosing with formoterol/budesonide com-
bined product and reduces the cost of exacerbations manage-
ment by 43%.
PAA4
PHARMACOECONOMIC ANALYSIS OF USE OF A SIMBICORT
TURBUHALER AND SERETIDE MULTIDISK OF ASTHMA
PATIENTS
Kulikov A, Lomakin A, Krysanov I, Polivanov V
Moscow Medical Academy, Moscow, Russia
OBJECTIVES: To perform cost–effectiveness analysis of combos
budesonide/formoterol in different dosing regimes and ﬁxed
dosing salmoterol/ﬂuticasone in bronchial asthma (BA) treat-
ment in Russia. METHODS: Modeling study based on the
results of international randomized double blind study of 6 coun-
tries outpatient practice published by R. Albers, et al.* Three
group patients with BA were assessed: group 1 (n = 219)—
adjustable maintenance dosing budesonide/formoterol 160/4,5
micrograms, 1st month—2 inhalations twice a day and next 6
month—on average 3,4 inhalations a day; group 2 (n = 215)—
ﬁxed dosing the same product, 2 inhalations twice a day and
group 3 (n = 224)—ﬁxed dosing salmeterol/ﬂuticasone 50/250
micrograms, 1 inhalation twice a day. Direct medical costs (DC)
were taken into account from the health care system point of
view and consisted of expenditures on products usage and treat-
ment of complications. Effectiveness (E) was the average percent
of pts with a week of well-controlled asthma based on clinical
study results. There was a signiﬁcant positive dynamics in all
groups accordingly: E1 = 65%, E2 = 50% and E3 = 55%.
RESULTS: Direct cost (DC) for each group were: DC1 = 364
EUR, DC2 = 417 EUR and DC3 = 420 EUR respectively. Cost—
effectiveness ratio (CER): CER1 = 5.58, CER2 = 8.34 and CER3
= 7.63 EUR per percent of pts with a week of well-controlled
asthma respectively as well. CONCLUSION: adjustable mainte-
nance dosing budesonide/formoterol is the best choose to treat
pts with BA based on cost-effectiveness analysis results.
*-R. Albers, et al. Current medical research and opinion.
2004:20:225–40.
PAA5
ECONOMIC EVALUATION OF A NEW AIRWAY
INFLAMMATION MONITOR IN THE DIAGNOSIS AND
MANAGEMENT OF ASTHMA IN GERMANY
Berg J1, Lindgren P1, Jönsson B2
1Stockholm Health Economics, Stockholm, Sweden, 2Stockholm
School of Economics, Stockholm, Sweden
OBJECTIVES: Fractional exhaled nitric oxide (FENO) is a
measure for the airway inﬂammation underlying asthma, which
can be used for both diagnosis and monitoring the effect of anti-
inﬂammatory treatment. The objective of this study was to assess
the cost-effectiveness of NIOX MINO®, a portable non-invasive
FENO monitor, in asthma diagnosis and management.
METHODS: Two decision trees were constructed that capture
the different alternatives and consequences in asthma diagnosis
and management. Reﬂecting available clinical data on diagnostic
precision, NIOX MINO was compared against standard diag-
nostics, including spirometry, reversibility testing, bron-
choprovocation and sputum eosinophil count. The impact of
asthma management with NIOX MINO on inhaled steroid use,
exacerbations and hospitalisations was compared against stan-
dard guidelines (spirometry) over a 1-year timeframe. A German
payer perspective was chosen, focusing on direct medical costs
taken from published sources in 2006. Effectiveness was mea-
sured in quality-adjusted life-years (QALYs). RESULTS: Asthma
diagnosis based on NIOX MINO results in a cost of €12 per
patient, including the cost of false diagnoses, compared to €20
for standard diagnostics. If NIOX MINO is conducted in addi-
tion to standard tests, the incremental cost would be up to €7
per patient. Asthma management with NIOX MINO instead of
standard guidelines is a dominant strategy. In mild to severe
patients, it results in cost-savings of €140 per patient and year
and 0.06 QALYs gained. In a more severe population, manage-
ment with NIOX MINO would save costs of €260 per patient
and lead to 0.004 QALYs gained. CONCLUSIONS: Asthma
diagnosis based on NIOX MINO alone is less costly and more
accurate than standard diagnostic methods, while the addition
of NIOX MINO to spirometry increases costs marginally. The
use of NIOX MINO in treatment decisions is less costly than
asthma management based on standard guidelines, while pro-
viding the same health beneﬁts.
